PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance
FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.
- FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.
- Because head and neck cancer is often diagnosed at later stages, treatment is often more difficult and more invasive.
- There are exciting things happening in clinical research for head and neck cancer therapies, said Amanda Hollinger, Executive Director of HNCA.
- In 2018, head and neck cancer surpassed cervical cancer as the most common HPV-attributed cancer in the United States.